Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EuroNet-PHL-C2 in Classical Hodgkin Lymphoma in Children and Adolescents
NCT02684708Phase 3Completed
- Sponsor
- Justus Liebig University Giessen
- Start
- Oct 2015
- Primary completion
- Oct 2024
- Modality
- DNA Intercalators/Alkylators
- Countries
- 19
01
Overview
A Phase 3 trial of etoposide, doxorubicin in classical Hodgkin lymphoma (cHL), sponsored by Justus Liebig University Giessen. Started Oct 2015; status: completed.
02
Drugs
etoposidedoxorubicin
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT02684708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02684708.